CCSD Code XR130: Transjugular/Transfemoral Plugged Liver Biopsy

Key Takeaways

CCSD code XR130 covers both transjugular and transfemoral routes for plugged liver biopsy under one code.

Plugged biopsy technique is typically indicated when coagulopathy or ascites makes percutaneous biopsy high-risk.

Pre-authorisation from the insurer is generally required before performing this procedure under private medical insurance.

Imaging guidance such as fluoroscopy may need to be coded separately alongside CCSD code XR130.

Accurate documentation of clinical indication, route, and technique is essential for successful PMI claim submission.

CCSD code XR130 is one of the more specialised entries in the UK private healthcare billing schedule – and for good reason. The transjugular or transfemoral plugged liver biopsy it describes is an interventional radiology procedure reserved for patients where the standard percutaneous approach carries meaningful clinical risk. For UK private practice teams billing under the CCSD (Clinical Coding and Schedule Development) Group’s schedule, understanding when and how to apply CCSD code XR130 correctly can prevent claim delays, rejections, and documentation shortfalls.

This guide covers the procedure itself, the correct coding application for CCSD code XR130, documentation requirements, related codes, private medical insurance (PMI) considerations, and how practice management software supports CCSD billing workflows in UK interventional radiology settings.

CCSD Code XR130: Procedure Overview and Clinical Context

CCSD code XR130 is formally titled Transjugular/Transfemoral Plugged Liver Biopsy(ies) in the CCSD Schedule of Procedures and Interventions. Both access routes – transjugular (via the internal jugular vein) and transfemoral (via the femoral vein) – fall under this single code. The “plugged” designation refers to a technique in which the biopsy needle track is embolised, typically with gel foam or coils, immediately after tissue sampling to reduce bleeding risk.

CCSD Code XR130: Transjugular vs Transfemoral Route

Both vascular access routes achieve the same clinical objective: reaching hepatic parenchyma without traversing the peritoneal cavity. The transjugular route is more common in UK interventional radiology practice, with the introducer sheath placed through the right internal jugular vein and advanced into a hepatic vein under fluoroscopic guidance. The transfemoral approach is used in anatomical variants or when jugular access is not feasible.

Because the CCSD technical guide explicitly includes both access routes within the XR130 code description, coders should not attempt to differentiate between them for billing purposes. The code applies regardless of which venous route was used, provided the procedure was performed under image guidance with plugging of the biopsy tract.

CCSD Code XR130: Why Plugged Biopsy Is Used

The plugged technique is generally indicated when patients present with coagulopathy, thrombocytopenia, or significant ascites – conditions in which a percutaneous (transabdominal) liver biopsy carries elevated haemorrhagic risk. According to guidance from the British Society of Interventional Radiology (BSIR) and British Association for the Study of the Liver (BASL), these clinical features represent the primary indications for a vascular approach. Clinicians should document the specific contraindication to percutaneous biopsy clearly in the patient record, as this justification may be requested by the insurer during claims review.

Histopathology processing of the liver core specimen proceeds as standard following collection. The biopsy yield from CCSD code XR130 procedures is comparable to percutaneous methods when performed by an experienced interventional radiologist under fluoroscopy guidance, though this remains subject to operator technique and patient anatomy. For private clinics managing hepatology referrals, the clinical record should capture both the technical approach and the clinical rationale at the point of procedure.

Documentation Requirements for CCSD Code XR130

Claims submitted under CCSD code XR130 are more likely to be queried if the clinical record is incomplete. PMI providers expect the procedural documentation to justify the choice of vascular biopsy over the percutaneous standard, and several specific data points should be present before the invoice is raised.

CCSD Code XR130: Required Documentation Checklist

The following elements should appear in the patient record and procedure report for any XR130 claim submission. Each item maps to a question an insurer’s clinical reviewer may ask when assessing medical necessity.

• Clinical indication: Documented contraindication to percutaneous biopsy – typically coagulopathy (INR, platelet count), significant ascites, or anatomical factors preventing safe transabdominal access.
• Access route: State explicitly whether transjugular or transfemoral venous access was used, and document the reason if the transfemoral route was chosen over the transjugular.
• Image guidance used: Confirm fluoroscopic guidance was employed throughout the procedure. This is clinically standard for CCSD code XR130 and should appear in the procedure report.
• Plugging technique: Describe the embolisation material used (gel foam, coils, or equivalent) and document that tract plugging was performed at the end of tissue sampling.
• Number of passes: Record the number of biopsy passes made. The XR130 code covers biopsy(ies) plural, but the procedural note should confirm the total passes for clinical and audit purposes.
• Specimen quality: Note the adequacy of the tissue core for histopathological analysis, particularly if multiple passes were required.
• Referring diagnosis: Include the ICD-10 diagnosis code(s) supporting the clinical indication – for example, K74.60 (liver cirrhosis, unspecified) or K74.69 (other cirrhosis) for chronic liver disease workup, or a relevant hepatitis or elevated liver enzyme code.

Practices using structured client records can template these documentation fields so that the procedural note captures all required elements at the time of entry, rather than requiring retrospective completion when a claim is queried. The compliance management tools within practice software can flag incomplete records before invoice generation, reducing the risk of late-discovered omissions.

CCSD Code XR130: Related Codes and Bundling Considerations

Interventional radiology procedures rarely stand alone in a CCSD claim. For XR130, the most common billing question involves whether imaging guidance and vascular access codes can be claimed alongside the primary procedure code. The answer depends on the specific insurer’s fee schedule and whether the CCSD technical guide treats these elements as included or separately billable.

Fluoroscopy and Imaging Guidance Alongside CCSD Code XR130

Fluoroscopic guidance is technically integral to the transjugular approach, but whether it is included within the XR130 fee or separately codeable varies between insurers. Some PMI providers follow the CCSD schedule’s bundling rules strictly, treating imaging guidance as part of the procedure. Others permit a separate imaging guidance code – typically from the XR radiology section – when the fluoroscopy represents a distinct and additional service beyond standard procedural imaging.

Clinicians and billing teams should review the specific insurer’s fee schedule before adding imaging guidance codes. The Bupa code search portal allows verification of Bupa’s current CCSD bundling position, and similar verification tools exist for AXA Health, Aviva, and Vitality. Where doubt exists, contact the insurer’s provider relations team directly before submission rather than after a rejection. Pabau’s Bupa CCSD codes reference provides additional context on how major UK insurers handle CCSD bundling rules.

CCSD Code XR130: ICD-10 Diagnosis Codes Commonly Paired

Every CCSD claim requires an associated diagnosis code. For XR130 procedures, the ICD-10 code should reflect the underlying hepatic condition driving the biopsy request. The following are frequently encountered pairings in UK private hepatology practice:

• K74.60 – Unspecified cirrhosis of liver: used when chronic liver disease is established but aetiology is under investigation
• K74.69 – Other cirrhosis of liver: for documented cirrhosis of specified non-viral, non-alcoholic origin
• K71.51 – Toxic liver disease with chronic active hepatitis: when drug or toxin exposure is the suspected aetiology
• B18.2 – Chronic viral hepatitis C: for hepatitis C-related fibrosis staging biopsies
• B18.1 – Chronic viral hepatitis B: equivalent for hepatitis B assessment
• K76.0 – Fatty (change of) liver: in non-alcoholic fatty liver disease (NAFLD) staging workup
• R74.0 – Elevation of liver transaminase levels: where biopsy is indicated by abnormal LFTs without confirmed diagnosis

The ICD-10 code should represent the patient’s current clinical state, not the anticipated biopsy finding. Assigning a definitive diagnosis code before the histopathology result is available is a documentation risk and may need amendment after the report is received. For practices managing claims workflows across multiple hepatology referrals, maintaining a consistent ICD-10 pairing library for XR130 procedures can reduce coder variation and improve first-pass acceptance rates.

Streamline Your CCSD Billing Workflows

Pabau helps UK private clinics manage CCSD code entry, PMI claim submission, and documentation completeness in one platform – reducing the administrative burden on your billing team.

Book a demo

Private Medical Insurance Billing for CCSD Code XR130

UK private medical insurance providers treat interventional radiology procedures differently from outpatient consultations, and CCSD code XR130 sits firmly in the category that requires active insurer engagement before the procedure takes place. Getting this process wrong – even by a small margin in timing or documentation – can result in partial payment, delayed settlement, or full claim rejection.

Pre-Authorisation Requirements for CCSD Code XR130

Pre-authorisation is generally required by major UK PMI providers before a transjugular or transfemoral plugged liver biopsy is performed. This applies across Bupa, AXA Health, Aviva, Vitality Health, WPA, and Cigna, though the specific authorisation process varies between insurers. Clinics should request authorisation with reference to the CCSD code XR130 description – “Transjugular/Transfemoral Plugged Liver Biopsy(ies)” – to ensure the insurer records the correct procedure against the authorisation number.

Supporting the authorisation request with the clinical justification for the vascular approach (rather than percutaneous) strengthens the case for approval. Specifically, include the relevant coagulation parameters, platelet count, or ascites assessment that supports the procedural decision. Some insurers require this documentation to be submitted with the authorisation request rather than being accepted retrospectively. For practices building out their private practice workflows, establishing a pre-authorisation template for XR130 saves significant time when requests arrive from hepatology or gastroenterology referrers.

CCSD Code XR130: Fee Schedule References by Insurer

CCSD-based fee schedules are maintained individually by each insurer, and reimbursement amounts for XR130 may differ between providers. Clinicians and billing teams should verify current fee levels directly from insurer portals before quoting patients or setting procedure pricing expectations. Useful references include:

• Vitality Health fee finder – CCSD-based fee lookup by procedure code
• Healix fee schedule – includes CCSD unbundling guidelines relevant to interventional procedures
• Bupa procedure codes and fee schedule – Pabau’s reference guide for Bupa CCSD billing

Fee schedules are updated periodically, and clinics that rely on memorised rates rather than current schedule references are at risk of either undercharging or submitting invoices that exceed the insurer’s allowed amount. For practices transitioning from NHS to private settings, establishing a habit of annual fee schedule reviews is a fundamental billing governance step. The CCSD Group maintains its schedule at ccsd.org.uk, providing the authoritative source for code descriptions and any additions or amendments to the interventional radiology section.

CCSD Code XR130: Invoice Submission and the Healthcode Pathway

The majority of UK PMI invoices are submitted electronically through the Healthcode EDI (electronic data interchange) network. For CCSD code XR130, the invoice should carry the authorisation number, the CCSD procedure code, the ICD-10 diagnosis code(s), the date of service, and the practitioner’s GMC registration number. Errors in any of these fields – particularly mismatches between the authorised procedure and the invoiced code – are a common reason for claim suspension in Healthcode’s validation layer.

Practices with integrated claims management software can validate these fields at the point of invoice creation rather than discovering errors after submission. This matters for XR130 specifically because the procedure’s clinical complexity means the invoicing team may be working from a consultant’s shorthand description rather than a complete procedure report – a gap that structured billing workflows can close.

CCSD Billing Workflow: From Referral to Paid Claim for XR130

Mapping the end-to-end billing workflow for an XR130 procedure reveals where delays most commonly occur in UK private interventional radiology practice. Most billing failures do not happen at the coding stage – they happen earlier, when patient eligibility is not confirmed, or later, when documentation does not match the submitted code.

CCSD Code XR130 Billing: Step-by-Step Workflow

1. Patient eligibility check: Confirm the patient’s PMI policy covers interventional radiology procedures and that the policy is active. Some policies have sub-limits on interventional procedures that differ from standard inpatient surgical coverage.
2. Referral and clinical justification: Ensure the referring clinician’s letter documents the clinical indication for a vascular approach. Hepatology referrers are usually thorough here, but a clear contraindication statement is essential.
3. Pre-authorisation request: Submit the pre-authorisation request to the insurer with the CCSD code XR130 description and supporting clinical evidence. Record the authorisation reference number against the patient record immediately on receipt.
4. Procedure and contemporaneous documentation: Complete the procedure report immediately after the session, capturing all elements from the documentation checklist above. Do not rely on retrospective completion from theatre notes.
5. Invoice generation: Generate the CCSD invoice with the authorisation number, XR130 code, ICD-10 diagnosis code(s), and any separately coded imaging guidance or anaesthetic fees if applicable.
6. Healthcode submission: Submit through the EDI pathway. Confirm receipt and track the claim to settlement. Flag any query or suspension immediately – most insurers operate a response window of 5-10 working days for queried claims.

For clinics managing multiple consultants across interventional radiology, hepatology, and gastroenterology, a centralised billing system that connects practice management with CCSD code entry removes the reliance on individual clinicians to supply correct codes. The billing team can work from structured templates that present the relevant CCSD codes for the procedure type, with the XR130 pre-loaded for transvascular liver biopsy sessions.

How Practice Management Software Supports CCSD Code XR130 Billing

UK private practices billing CCSD code XR130 face a compounding challenge: a technically complex procedure, a documentation-heavy insurer review process, and a billing pathway that touches multiple staff roles from the clinical team through to the accounts department. Practice management software that supports CCSD workflows reduces the points of failure in this chain.

Pabau supports CCSD code entry and private medical insurance billing workflows for UK private clinics, allowing billing teams to record procedure codes, attach ICD-10 diagnosis codes, and manage the pre-authorisation reference against the patient record in one place. The platform’s digital forms functionality can be configured to capture the key clinical data points required for XR130 documentation at the point of procedure, reducing the risk of retrospective gaps that trigger insurer queries.

For practices managing a high volume of PMI billing across specialties, the ability to filter and report on claim status by CCSD code is operationally valuable. An outstanding XR130 claim that has been suspended for a documentation query can sit unresolved for weeks without a systematic review process. Practices that have transitioned to integrated practice management platforms typically report faster identification of claim queries compared to those relying on spreadsheet-based tracking, because the claim status is visible alongside the patient record rather than in a separate billing log.

The Care Quality Commission (CQC) also expects private healthcare providers to maintain robust clinical record-keeping standards. Understanding the CQC’s role in private practice helps billing teams appreciate why documentation completeness is both a reimbursement requirement and a regulatory one. The same procedure note that satisfies the insurer’s clinical reviewer should also satisfy a CQC inspection of clinical records.

Expert Picks

Need a broader reference for Bupa CCSD billing workflows? Bupa CCSD Codes covers the full CCSD schedule as applied to Bupa claims, with guidance on code structure, invoicing requirements, and common query reasons.

Looking to streamline private medical insurance claim submissions? Claims Management Software explains how Pabau supports CCSD code entry, PMI billing, and Healthcode submission for UK private clinics.

Managing a multi-specialty private clinic with complex billing needs? Practice Management Software outlines how integrated platforms reduce billing errors and streamline CCSD-based invoicing workflows.

Conclusion

CCSD code XR130 occupies a specific and clinically justified role in the UK private healthcare billing schedule. For interventional radiology teams and the practice management staff supporting them, applying this code correctly requires more than knowing the procedure title – it requires a clear understanding of when the vascular approach is clinically appropriate, what documentation must accompany the claim, and how major PMI providers handle pre-authorisation and bundling for interventional procedures.

Getting the workflow right from referral through to claim settlement protects the practice’s revenue, reduces administrative rework, and ensures the clinical record reflects the complexity of the procedure performed. Reviewed against current CCSD Group schedule guidance and major UK insurer billing requirements.

Frequently Asked Questions